# Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

> **NCT03790332** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pharmacyclics LLC.** · enrollment: 59 (actual)

## Conditions studied

- Chronic Graft Versus Host Disease

## Interventions

- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT03790332
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-19
- **Primary completion:** 2025-10-09
- **Final completion:** 2025-10-09
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2025-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03790332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03790332, "Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03790332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*